ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

Share

Objective:

To evaluate the efficacy and safety of silevertinib as a first-line treatment for hard-to-treat EGFR non-small cell lung cancer variants.

Approach:
  • Study Overview: The study conducted by Dr. Julia Rotow at Dana-Farber Cancer Institute focused on silevertinib's potential as a new treatment option.
Key Findings:
  • Silevertinib may provide a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants.
  • The treatment shows encouraging activity in brain metastases.
  • Side effects associated with silevertinib are manageable.
Interpretation:

The findings suggest that silevertinib could be a viable option for patients with specific lung cancer variants.

Conclusion:

The study indicates potential benefits of silevertinib in treating challenging lung cancer cases.

Original Source(s)

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

  • July 1, 2026

Related Content

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms